• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

    11/14/24 4:32:01 PM ET
    $TRML
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TRML alert in real time by email
    SC 13G/A 1 sayw24111425_13ga.htm


      UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
     

    INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-
    1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934*

    (Amendment No. 2)

    Tourmaline Bio, Inc.
    (Name of Issuer)

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

    89157D105
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)



    CUSIP No. 89157D105
    13G
    Page 2 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 3 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Parent GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 4 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 5 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 6 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)*
     
     
    PN
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 7 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)*
     
     
    IN
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 8 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)*
     
     
    IN
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 9 of 16

    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)*
     
     
    IN
     
     
     
     

    * See Item 4


    CUSIP No. 89157D105
    13G
    Page 10 of 16

    Item 1(a).
    Name of Issuer:

    Tourmaline Bio, Inc. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    27 West 24th Street, Suite 702
    New York, NY 10010

    Item 2(a).
    Name of Person Filing:

    Viking Global Investors LP (“VGI”),
    Viking Global Opportunities Parent GP LLC (“Opportunities Parent”),
    Viking Global Opportunities GP LLC (“Opportunities GP”),
    Viking Global Opportunities Portfolio GP LLC (“Opportunities Portfolio GP”),
    Viking Global Opportunities Illiquid Investments Sub-Master LP (“VGOP”),
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the “Reporting Persons”)

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: 600 Washington Blvd., Floor 11, Stamford, Connecticut 06901.

    Item 2(c).
    Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

    Item 2(d).
    Titles of Classes of Securities:

    Common stock, par value $0.0001 per share (“Common Stock”)

    Item 2(e).
    CUSIP NUMBER: 89157D105

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:


    (a)
    ☐ Broker or dealer registered under Section 15 of the Exchange Act


    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act


    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act


    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940


    (e)
    ☐ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)


    (f)
    ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)


    (g)
    ☐ Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G).


    CUSIP No. 89157D105
    13G
    Page 11 of 16


    (h)
    ☐ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.


    (i)
    ☐ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.


    (j)
    ☐ Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership:


    A. VGI


    (a)
    Amount beneficially owned: 0


    (b)
    Percent of Class: 0.0%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 0


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 0

    VGI provides managerial services to VGOP. VGI has the authority to dispose of and vote the shares of Common Stock directly owned by VGOP. VGI does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, VGI may be deemed to beneficially own the shares of Common Stock directly held by VGOP.


    B. Opportunities Parent
     

    (a)
    Amount beneficially owned: 0
     

    (b)
    Percent of Class: 0.0%
     

    (c)
    Number of shares as to which such person has:
     

    (i)
    Sole power to vote or to direct the vote: 0


    CUSIP No. 89157D105
    13G
    Page 12 of 16


    (ii)
    Shared power to vote or to direct the vote: 0


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 0
     
    Opportunities Parent serves as the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by VGOP. Opportunities Parent does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock directly held by VGOP.

    C. Opportunities GP


    (a)
    Amount beneficially owned: 0


    (b)
    Percent of Class: 0.0%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 0


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by VGOP. Opportunities GP does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock directly held by VGOP.

    D. Opportunities Portfolio GP


    (a)
    Amount beneficially owned: 0


    (b)
    Percent of Class: 0.0%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 0


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 0


    CUSIP No. 89157D105
    13G
    Page 13 of 16

    Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock directly owned by VGOP. Opportunities Portfolio GP does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock directly held by VGOP.

    E. VGOP


    (a)
    Amount beneficially owned: 0


    (b)
    Percent of Class: 0.0%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 0


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 0

    VGOP has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP.

    Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP.

    F. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet


    (a)
    Amount beneficially owned: 0


    (b)
    Percent of Class: 0.0%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 0


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock.

    Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock directly held by VGOP.


    CUSIP No. 89157D105
    13G
    Page 14 of 16


    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    The response to Item 4 is incorporated by reference herein.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
     Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(c))

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     

    CUSIP No. 89157D105
    13G
    Page 15 of 16

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     Dated: November 14, 2024    
         
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).
     
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).


    CUSIP No. 89157D105
    13G
    Page 16 of 16

    EXHIBIT A - JOINT FILING AGREEMENT

    This joint filing agreement is made and entered into as of this 14th day of November, 2024, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

    The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Forms 3, 4, or 5 or Schedules 13D or 13G, and any and all amendments thereto and any other documents relating thereto (collectively, the “Filings”) as required to be filed pursuant to the Securities Exchange Act of 1934, as amended. The parties to this Agreement further agree and covenant that each will fully cooperate with such other parties in the preparation, timely filing, and delivery of all such Filings.

    IN WITNESS WHEREOF, the parties hereto have executed this agreement as of the date first set forth above.

    Dated: November 14, 2024
       
         
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).
     
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
     


    Get the next $TRML alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRML

    DatePrice TargetRatingAnalyst
    4/23/2025$70.00Buy
    Chardan Capital Markets
    3/6/2025$42.00Outperform
    Wedbush
    12/6/2024$50.00Outperform
    BMO Capital Markets
    11/11/2024$48.00 → $49.00Buy
    H.C. Wainwright
    12/15/2023$41.00Buy
    Jefferies
    12/4/2023$48.00Buy
    H.C. Wainwright
    11/17/2023$43.00Buy
    Truist
    10/31/2023$50.00Buy
    Guggenheim
    More analyst ratings

    $TRML
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Kulkarni Sandeep Chidambar bought $26,418 worth of shares (1,779 units at $14.85) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/22/24 4:22:14 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO Kulkarni Sandeep Chidambar bought $71,998 worth of shares (5,221 units at $13.79) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/20/24 6:09:47 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:46:12 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:05:20 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 4:32:01 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Tourmaline with a new price target

      Chardan Capital Markets initiated coverage of Tourmaline with a rating of Buy and set a new price target of $70.00

      4/23/25 8:18:16 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Tourmaline with a new price target

      Wedbush initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $42.00

      3/6/25 7:32:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Tourmaline with a new price target

      BMO Capital Markets initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $50.00

      12/6/24 8:19:37 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    SEC Filings

    See more
    • Tourmaline Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/20/25 9:02:35 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tourmaline Bio Inc.

      SCHEDULE 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      5/15/25 4:22:00 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tourmaline Bio Inc.

      10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/2/25 8:12:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Kulkarni Sandeep Chidambar

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      2/4/25 4:19:06 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Robinson Ryan F.

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:34 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CBO, GC and Secretary Middlekauff W Bradford

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:21 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Leadership Updates

    Live Leadership Updates

    See more

    $TRML
    Financials

    Live finance-specific insights

    See more
    • Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). "We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of card

      1/10/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

      Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa

      4/2/24 7:00:00 AM ET
      $AVTX
      $TRML
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

      NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines

      12/14/23 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care